Cadus Pharmaceutical Corporation Achieves Research Milestone with SmithKline Beecham Collaboration

Cadus Pharmaceutical Corporation has announced a significant research milestone in its collaboration with SmithKline Beecham Corporation, a major player in the pharmaceutical industry. The milestone, achieved in 1998, pertains to the identification of ligands for orphan G-protein coupled receptors extracted from the human genome. This breakthrough is a direct result of Cadus's innovative core yeast technology, which enables rapid evaluation of peptides and small molecules for their ability to stimulate these receptors. The achievement has triggered a $1.0 million payment to Cadus, underscoring the potential of this collaboration.

Key Takeaways:

• Cadus Pharmaceutical Corporation, in collaboration with SmithKline Beecham Corporation, has achieved a significant research milestone in the identification of ligands for orphan G-protein coupled receptors extracted from the human genome.
• The milestone was achieved in 1998 and triggers a $1.0 million payment to Cadus, highlighting the potential of this collaboration.
• Cadus's core yeast technology allows for the rapid evaluation of peptides and small molecules for their ability to stimulate orphan receptors, a key step in determining their suitability for drug discovery.
• The collaboration combines Cadus's expertise in elucidating orphan G-protein coupled receptors with SmithKline Beecham's experience in discovering novel molecular targets.
• Cadus is utilizing its proprietary Self-Selecting Combinatorial Library (SSCL(TM)) technology to identify protein and small molecule ligands for newly discovered receptors of unknown function.
• The ligands identified are used to help determine the functions of the orphan receptors and to determine whether they are useful targets for drug discovery.
• Cadus Pharmaceutical Corporation is a biotechnology company engaged in genomics research and the discovery of novel small molecule therapeutics, with a focus on exploiting the similarities between the yeast and human genomes to create drug discovery tools and elucidate gene function.
• The company has established collaborations with pharmaceutical and biotechnology partners across various therapeutic areas, including allergy/asthma, inflammatory disorders, cardiovascular diseases, and cancer.

Statistics:

• $1.0 million: The payment triggered by Cadus's achievement of the research milestone in its collaboration with SmithKline Beecham Corporation.
• 1998: The year in which the research milestone was achieved.
• 5 years: The duration of Cadus's functional genomics collaboration with SmithKline Beecham Corporation.
• July 17, 1996: The date on which Cadus filed its prospectus with the Securities and Exchange Commission.

Sources:

• PRNewswire, January 12 /PRNewswire/ --
• Cadus Pharmaceutical Corporation Home Page (http://www.cadus.com)
• Noonan Russo Home Page (http://www.noonanrusso.com)